Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-09-01
1996-10-08
Tsang, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546118, 546336, 546300, 5483071, 5483097, 5483064, C07D47104, A61K 31435
Patent
active
055631517
DESCRIPTION:
BRIEF SUMMARY
This invention relates primarily to novel substituted amino acid derivatives that possess pharmaceutical activity as antagonists of PAF.
Platelet activating factor (PAF) is a bioactive phospholipid which has been identified as 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphoryl choline. PAF is released directly from cell membranes and mediates a range of potent and specific effects on target cells resulting in a variety of physiological responses which include hypotension, thrombocytopenia, bronchoconstriction, circulatory shock, and increased vascular permeability (oedema/erythema). It is known that these physiological effects occur in many inflammatory and allergic diseases and PAF has been found to be involved in a number of such disorders including asthma, endotoxin shock, adult respiratory distress syndrome, glomerulonephritis, immune regulation, transplant rejection, gastric ulceration, psoriasis, and cerebral, myocardial and renal ischemia. Thus the compounds of the invention, by virtue of their ability to antagonise the actions of PAF, should be of value in the treatment of any of the above conditions and any other conditions in which PAF is implicated (e.g. embryo implantation).
Compounds that have been disclosed as possessing activity as PAF antagonists include compounds which are structurally related to the PAF molecule such as glycerol derivatives (EP-A-0238202), and heterocyclic compounds such as 5-oxy derivatives of tetrahydrofuran (U.S. Pat. No. 4,888,337) and 2,5-diaryl tetrahydrofurans (EP-A-0144804). Recently a more potent 2,5-diaryl tetrahydrofuran derivative, (trans)-2-(3-methoxy-5-methylsulphonyl-4-propoxyphenyl)-5-(3,4,5-trimethox yphenyl)tetrahydrofuran (L-659,989) has been disclosed (EP-A-0199324). In our International patent application no. WO 91/17157 we disclose a series of .gamma.-butyrolactol derivatives as PAF antagonists. The compounds of WO 91/17157 differ from the 5-oxy derivatives of tetrahydofuran described in U.S. Pat. No. 4,888,337 and from the 2,5-diaryl tetrahydrofurans such as L-659,989, in that they feature an appended heterocycle with an unsubstituted sp.sup.2 nitrogen atom. There are a number of other PAF antagonists, in addition to those of WO 91/17157, for which the presence of a heterocyclic sp.sup.2 nitrogen atom appears to be an important requirement for activity (Whittaker, M., Curr. Opin. Thera. Patents 2(5), 583-623 (1992)).
For the compounds of the present invention the presence of a heterocyclic group possessing an unsubstituted sp.sup.2 nitrogen atom is also a requirement for PAF antagonist activity. However, the compounds of the present invention differ from the other PAF antagonists refered to above in that they are amino acid derivatives.
The present invention provides novel and useful substituted amino acid derivatives and their pharmaceutically acceptable acid addition salts, and pharmaceutical uses thereof as PAF antagonists.
According to a first aspect of the invention there is provided a compound of general formula I: ##STR2## wherein:
W represents pyrid-3-yl, benzimidazol-1-yl, imidazo[4,5-c]pyridin-1-yl, imidazo[4,5-c]pyridin-3-yl and imidazo[4,5-c]pyridin-5-yl optionally substituted with one or more --C.sub.1 -C.sub.6 alkyl substituents;
Z represents: carbon atoms which may be a straight or branched-chain provided that, when Z represents a branched chain at least two carbon atoms separate W from the group Q, wherein the said group is either unsubstituted or substituted by one or more substituents selected from hydroxy, --OC.sub.1 -C.sub.6 alkyl, --SC.sub.1 -C.sub.6 alkyl and halo; or by one or more substituents selected from hydroxy, --OC.sub.1 -C.sub.6 alkyl, halo and nitrile, wherein q is an integer from 0-3, r is an integer from 0-3 and U is --O--, --S-- or a furandiyl, tetrahydrofurandiyl, thiophenediyl, tetrahydrothiophenediyl, thiazolediyl, tetrahydrothiazolediyl, piperazinediyl, piperidinediyl, cyclopentanediyl, cyclohexanediyl, cycloheptenediyl or benzenediyl group (provided that, when U is a 1,4-benzenediyl group q is not an in
REFERENCES:
patent: 4288536 (1981-09-01), Goettert et al.
patent: 4610983 (1986-09-01), Takagawa et al.
patent: 5071837 (1991-12-01), Doherty et al.
patent: 5158866 (1992-10-01), Simpson et al.
patent: 5215968 (1993-06-01), Nickel et al.
Lauf, P. W. Research Disclosure 29963 (Mar. 1989).
Bowles Stephen A.
Miller Andrew
Whittaker Mark
British Biotech Pharmaceuticals Limited
Tsang Cecilia
Wong King L.
LandOfFree
Amino acid derivatives as paf-receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino acid derivatives as paf-receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino acid derivatives as paf-receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-57547